SBL
PRVL

Sargent Bickham Lagudis’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Sargent Bickham Lagudis’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed -$2K – 1013
2020
Q4 		$2K Hold
100
– – ﹤0.01% 824
2020
Q3 		$1K Buy
+100
New +$1.34K ﹤0.01% 782

Sargent Bickham Lagudis's PRVL Position: Q1 2021 in Review

Sargent Bickham Lagudis sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 100 shares — an estimated $2K sold.

Sargent Bickham Lagudis first reported a position in PRVL in Q3 2020 and held it in 2 quarters. The position peaked at $2K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Sargent Bickham Lagudis reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 100 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $2K.
  • Sargent Bickham Lagudis first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Sargent Bickham Lagudis's Prevail Therapeutics Inc. Common Stock position peaked at $2K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2021, filed 24 May 2021.